Rhythm (RYTM) Q1 2026 Earnings Call Transcript

Rhythm Pharmaceuticals reported Q1 2026 revenue of $60.1 million, up 5% sequentially, driven by a 27% increase in international sales to $23.2 million and continued growth in reimbursed patients. The company said its acquired hypothalamic obesity launch is off to a strong start, with more than 150 start forms in six weeks, 110 unique prescribers, and early reimbursement approvals, while EU marketing authorization and Japanese NDA acceptance expand the opportunity. Management kept 2026 non-GAAP operating expense guidance at $385 million-$415 million and said cash of $341 million should fund operations for at least 24 months.

Analysis

RYTM is shifting from a single-product orphan-drug story into a multi-region launch compounding machine, and the market is likely underestimating how much of the 2026/27 re-rating comes from operating leverage rather than just unit growth. The key second-order effect is that acquired HO expands the physician graph materially: once endocrinologists are activated on one patient, the marginal cost of finding additional patients in their practice drops sharply, which should improve persistence and script density into 2H26 as reimbursement policies formalize.

The bigger strategic advantage is that Europe and Japan are not just future revenue lines; they de-risk the narrative that U.S. launch pacing is a one-quarter event. Early-access cohorts in Europe create published real-world evidence before full market access, which should shorten payer skepticism and compress adoption lag in 2027. In Japan, the unusually fast regulatory cadence matters more than the absolute timing — it signals a global label/medical-need arbitrage that competitors in rare endocrinology will struggle to replicate.

The main bear case is not efficacy; it is launch conversion velocity versus cost inflation. SG&A is likely to stay elevated for several quarters because the sales force build is front-loaded, so any slowdown in payer policy codification or a hollowing-out after trial conversions will show up quickly in gross profit progression. Near term, the stock is vulnerable to a classic rare-disease launch fade if Q2 data show that non-trial starts normalize too quickly or if the prescriber base remains broad but shallow.

Consensus may be too focused on the first-six-weeks start-form count and not enough on the fact that this franchise now has three separate option values: U.S. HO policy maturation, Europe reimbursement rollout, and Japan approval. If those occur in sequence, the revenue base should look much more durable by year-end than current sell-side models likely assume. The risk/reward is favorable as long as investors can tolerate a 1-2 quarter digestion period while reimbursement catches up to demand creation.

Key Decisions for Investors

• Go long RYTM into the next 4-8 weeks on launch-follow-through expectations; use the stock weakness from any 'too early to tell' headlines as an entry point, with upside driven by Q2 conversion data and June updates.
• Add a call spread in RYTM (3-6 month tenor) to express upside from HO reimbursement normalization and international launch optionality; risk is capped if script growth stalls after trial conversions roll off.
• Pair trade: long RYTM / short another commercial-stage rare-disease name with slower launch execution and weaker geographic diversification, to isolate launch-quality alpha rather than market beta.
• Reduce or hedge RYTM after Q2 if non-trial HO start forms decelerate meaningfully versus the implied weekly cadence; that would signal the current pace was partly a bolus, not a durable run-rate.
• For a lower-risk expression, sell puts on RYTM into launch-related volatility if implied volatility remains elevated; thesis is that reimbursement and ex-U.S. milestones create a floor over the next 6-9 months.